Breaking news .. DSÖ General Director Dr. Tedros Adhanom Ghebreyesus held a video conference meeting with WHO epidemic experts at WHO’s headquarters in Geneva, Switzerland.
AA correspondent, Turkey, USA, Russia, China and the UK Vaccine Chief expert of the WHO scientific delegation, Dr. Soumya Swaminathan and WHO Deputy Director-General Dr. Mariangela Simao answered.
Stating that they closely follow the vaccine studies in the world, Swaminathan said, “It is really encouraging to see the progress in clinical trials all over the world. As you know, we currently have about 40 vaccine candidates at some stages of clinical trials and 10 of them are in the final phase PHASE-3 trials. last stage vaccines) will inform us of both the efficacy and safety of vaccines. ” said.
Dr. Swaminathan reported that the Kovid-19 vaccine will be available in December or early 2021 for regulators’ approval.
class=”cf”>
Scientist Swaminathan pointed out that having many candidates for Kovid-19 increases the chance of finding an effective and safe Kovid-19 vaccine.
WHO Deputy Director General and Drugs and Health Products Officer Dr. Simao said, “This vaccine will need to be licensed in the country where the trial was made, in the country where it was tested.” said.
Stating that WHO is working very closely with national regulatory authorities for the Kovid-19 vaccine, Simao noted that many steps should be taken for a widespread vaccination after the FAZ-3 trials are actually terminated.
US PHARMACEUTICAL COMPANY GIVEN THE “EMERGENCY USE” AUTHORIZATION FOR THE COVID-19 ANTIBODY TEST
Health technology firm Abbott, new type coronavirus (Kovid-19) announced that it received “emergency use” authorization in the USA for antibody testing.
The pharmaceutical and medical instrument manufacturer company, in its announcement on its official website, stated that the US Food and Drug Administration (FDA) approved the emergency use of the Kovid-19 antibody blood test produced in Abbott laboratories.
The American company stated that the “AdviseDX” test is used to identify a type of antibody called “Immunoglobulin M” in the blood to detect whether a person has been exposed to Kovid-19 before.
“EMERGENCY USE” AUTHORITY
class=”cf”>
The pharmaceutical company operating in 160 countries of the world was previously authorized for emergency use for 7 tests, including the test that can detect another type of antibody called “IgG”.
The FDA can authorize unapproved medicinal products for “emergency use” when there are no adequate or approved alternative medicines for the diagnosis and treatment of serious or life-threatening diseases.
—- .
